AIN

( DrugBank: - / KEGG DRUG: - )

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	17

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

trials per page:

Showing 1 to 10 of 17 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05730738 (ClinicalTrials.gov)	June 1, 2021	5/12/2021	Dalfampridine in Egyptian Patients With Multiple Sclerosis	Effect of Dalfampridine on Gait Impairment, Cognition and Fatigue in Egyptian Patients With Multiple ...	Multiple Sclerosis	Drug: Dalfampridine ER, 10 Mg Oral Tablet, Extended Release;Drug: Placebo	Ain Shams University	NULL	Recruiting	18 Years	N/A	All	100	N/A	Egypt
2	EUCTR2012-004019-29-PL (EUCTR)	07/10/2013	02/09/2013	Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis	A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose ...	Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multi ...	Product Name: Secukinumab Product Code: AIN457	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	380	Phase 2	United States;Portugal;Finland;Spain;Turkey;Russian Federation;Colombia;Switzerland;Italy;France;Cze ...
3	EUCTR2012-004019-29-DE (EUCTR)	19/09/2013	06/05/2013	Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis	A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose ...	Relapsing multiple sclerosis MedDRA version: 16.0;Level: PT;Classification code 10028245;Term: Multi ...	Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: ...	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	380	Phase 2	Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Cze ...
4	EUCTR2012-004019-29-PT (EUCTR)	02/08/2013	03/06/2013	Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis	A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose ...	Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multi ...	Product Name: Secukinumab Product Code: AIN457	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	380	Phase 2	Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Cze ...
5	EUCTR2012-004019-29-CZ (EUCTR)	18/07/2013	13/05/2013	Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis	A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose ...	Relapsing multiple sclerosis MedDRA version: 16.0;Level: PT;Classification code 10028245;Term: Multi ...	Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Other descriptive name: ...	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	380	Phase 2	Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Cze ...
6	EUCTR2012-004019-29-IT (EUCTR)	10/07/2013	11/01/2013	Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis	A Phase II, multicenter, randomized, double-blind, parallel group, placebocontrolled, adaptive dose- ...	Relapsing multiple sclerosis MedDRA version: 14.1;Level: HLT;Classification code 10052785;Term: Mult ...	Product Name: Secukinumab Product Code: AIN457 INN or Proposed INN: Secukinumab Product Name: Secukinum ...	NOVARTIS FARMA	NULL	Not Recruiting			Female: yes Male: yes	470	Phase 2	United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;Canada;Argentina;Po ...
7	EUCTR2012-004019-29-FI (EUCTR)	19/06/2013	16/05/2013	Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis	A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose ...	Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multi ...	Product Name: Secukinumab Product Code: AIN457	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	380	Phase 2	Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Cze ...
8	EUCTR2012-004019-29-SE (EUCTR)	19/06/2013	12/04/2013	Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis	A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose ...	Relapsing multiple sclerosis MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multi ...	Product Name: Secukinumab Product Code: AIN457	Novartis Pharma AG	NULL	Not Recruiting			Female: yes Male: yes	380	Phase 2	Portugal;United States;Finland;Spain;Turkey;Russian Federation;Colombia;Italy;Switzerland;France;Cze ...
9	JPRN-JapicCTI-132178	01/6/2013		A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose ...	A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose ...	Multiple Sclerosis	Intervention name : AIN457 INN of the intervention : secukinumab Dosage And administration of the inte ...	Novartis Pharma K.K.	NULL		18	55	BOTH	380	Phase 2	NULL
10	NCT01874340 (ClinicalTrials.gov)	June 2013	28/5/2013	Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis	A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose ...	Multiple Sclerosis	Drug: Placebo;Drug: AIN457	Novartis Pharmaceuticals	NULL	Terminated	18 Years	55 Years	All	28	Phase 2	Belgium;Czech Republic;France;Italy;Japan;Poland;Russian Federation;Spain;Sweden;Turkey;Canada;Finla ...

First Previous1 2Next Last